SMAD3 and type 2 diabetes mellitus: In this study, we discovered that Smad3 is a therapeutic target for T2D and T2DN and Smad3-targeted therapy with a Smad3 inhibitor SIS3 can protect db/db mice from the development of T2D and T2DN.